S&P TSX Capped Composite...

US Dollar vs CAD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

PVLA Palvella Therapeutics Inc

17.20

0.32 (1.90%)

Pre Market

Last Updated: 03:52:45

Delayed by 15 minutes

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]

Exhibit 24.1

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics (NASDAQ:PVLA)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more Palvella Therapeutics Charts.

Palvella Therapeutics Inc News

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
Monday 10 February 2025 (2 days ago) • Edgar (US Regulatory)

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations to Include the Younger Pediatric Population, Children 3 to 5 Years Old
Monday 10 February 2025 (3 days ago) • GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Friday 7 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 424B3 - Prospectus [Rule 424(b)(3)]
Friday 17 January 2025 (4 weeks ago) • Edgar (US Regulatory)

Palvella Therapeutics Announces Publication of Results from Phase 2 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations in the Journal of Vascular Anomalies
Friday 10 January 2025 (1 month ago) • GlobeNewswire Inc.

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors
Wednesday 8 January 2025 (1 month ago) • Edgar (US Regulatory)

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Cutaneous Venous Malformations
Wednesday 8 January 2025 (1 month ago) • GlobeNewswire Inc.

Form 3/A - Initial statement of beneficial ownership of securities: [Amend]
Monday 6 January 2025 (1 month ago) • Edgar (US Regulatory)

Form S-1 - General form for registration of securities under the Securities Act of 1933
Tuesday 31 December 2024 (1 month ago) • Edgar (US Regulatory)

More Palvella Therapeutics Inc News Articles

International Endeavors (PK)

Anavex Life Sciences

Greater Cannabis (PK)

Adia Nutrition (PK)

Intergrated Cannabis Sol... (PK)

Green Leaf Innovations (PK)

Rennova Health (CE)

Moon Equity (PK)

Paradigm Oil and Gas (PK)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions